Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim Papp, Andrew Blauvelt, L. Puig, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1149-1158
Open Access | Times Cited: 16

Showing 16 citing articles:

Risankizumab: Mechanism of action, clinical and translational science
Yinuo Pang, Ronilda D’Cunha, Insa Winzenborg, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 14
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Risankizumab in Japanese patients with moderate‐to‐severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study
Yukari Okubo, Masamoto Murakami, Satomi Kobayashi, et al.
The Journal of Dermatology (2025)
Open Access | Times Cited: 1
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
JAMA Dermatology (2024)
Open Access | Times Cited: 5
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
Diamant Thaçi, Mamitaro Ohtsuki, Julia‐Tatjana Maul, et al.
Dermatology and Therapy (2025)
Open Access
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Activation of the interleukin-23/Th17 axis in major depression: a systematic review and meta-analysis
Calum D. Moulton, Mantas Malys, Christopher W. P. Hopkins, et al.
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 3
Expanding the Psoriasis Framework: Immunopathogenesis and Treatment Updates
Yvonne Nong, George Han, Jason E. Hawkes
Cutis (2024) Vol. 113, Iss. 2
Open Access | Times Cited: 2
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 2
GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis
Wilson Liao, April W. Armstrong, Kristina Callis Duffin
The Journal of Rheumatology (2024) Vol. 51, Iss. Suppl 2, pp. 89-92
Closed Access | Times Cited: 2
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score
Husein Husein‐ElAhmed, Sara Husein-ElAhmed
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 10, pp. 1148-1155
Closed Access | Times Cited: 1
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1259-1271
Open Access | Times Cited: 1
Therapy of moderate-to-severe plaque psoriasis
О. В. Жукова, S. I. Artemyeva
Meditsinskiy sovet = Medical Council (2024), Iss. 2, pp. 34-42
Open Access
Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review
Hio Fong Leong, Wenhui Wang, Fen Peng
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 3, pp. 262-269
Open Access
Page 1

Scroll to top